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Abstract
Background: Pleural tuberculosis (TB) diagnosis often requires invasive procedures such as pleural biopsy. The aim
of this study was to evaluate the role of real-time polymerase chain reaction (PCR) for the IS6110 sequence of M.
tuberculosis in pleural fluid specimens as a rapid and non-invasive test for pleural TB diagnosis.
Findings: For this cross-sectional study, 150 consecutive patients with pleural effusion diagnosed by chest
radiography, who were referred for diagnostic thoracocentesis and pleural biopsy and met eligibility criteria, had a
pleural fluid specimen submitted for real-time PCR testing. Overall, 98 patients had pleural TB and 52 had pleural
effusion secondary to other disease. TB diagnosis was obtained using acid-fast bacilli (AFB) smear or culture for
mycobacteria and/or histopathologic examination in 94 cases and by clinical findings in 4 cases. Sensitivity,
specificity, positive and negative predictive values of PCR testing for pleural TB diagnosis were 42.8% (95% CI 38.4 -
44.8), 94.2% (95% CI 85.8 - 98.0), 93.3% (95% CI 83.6 - 97.7), and 48.5% (95% CI 44.2 - 50.4), respectively. The real-
time PCR test improved TB detection from 30.6% to 42.9% when compared to AFB smear and culture methods
performed on pleural fluid specimens, although the best sensitivity was achieved by combining the results of
culture and histopathology of pleural tissue specimens.
Conclusion: The real-time PCR test of pleural fluid specimens is a useful and non-invasive additional assay for fast
diagnosis of pleural TB.
Introduction
Diagnosis of pleural tuberculosis (TB) remains a chal-
lenge due to its nonspecific clinical presentation and
paucibacillary nature. Conventional methods, such as
direct testing for acid-fast bacilli (AFB) and culture of
pleural fluid, lack sensitivity (less than 5% and 40%,
respectively) [1-3]. Despite improved detection rates
with new methods, high pleural fluid levels of adenosine
deaminase (ADA) may be found in other diseases, espe-
cially empyema and parapneumonic effusions, and there
is no established cut-off value for measurement of inter-
feron-gamma in pleural fluid [4,5].
Therefore, a definitive diagnosis of pleural TB still
depends on demonstration of M. tuberculosis or caseous
granulomas in pleural biopsy, an invasive method with
possible complications requiring specialized medical
care that is not widely available [6]. Nucleic acid ampli-
fication assays allow the direct detection of M. tubercu-
losis in clinical specimens within hours of their receipt
in the laboratory, providing a potential tool for diagnos-
ing paucibacillary forms of TB [7]. Although the role of
nucleic acid amplification tests has been reasonably well
defined in pulmonary tuberculosis, their place in
pleurisy evaluation is not clear [7,8]. Real-time polymer-
ase chain reaction (PCR) is a technology that has advan-
tages over conventional PCR testing, such as the fast
availability of results, decreased risk of contamination
and quantification of bacterial load [9].
In Brazil, TB has an initial presentation as a pleural
disease in about 9% of adults and is the main cause of
pleural effusion, corresponding to over 50% of cases
[10,11]. In this study, we evaluated the role of a real-
time PCR assay for the IS6110 sequence of M. tubercu-
losis in pleural fluid specimens to evaluate the efficiency
and practicality of the test for diagnosing pleural TB.
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Materials and methods
Study population
From January 2003 to July 2005, all patients presenting
with pleural effusion on chest radiography referred by
their clinicians to the Pulmonary Service for Diagnostic
Methods, Thoracic Diseases Institute/Clementino Fraga
Filho University Hospital Federal University of Rio de
Janeiro for diagnostic thoracocentesis were eligible for
the study. Inclusion criteria were age ≥ 18 years old,
absence of known history or clinical or radiographic evi-
dence of renal, cardiac or liver failure, and no known
diagnosis of cancer or TB at the moment of enrollment.
All included patients signed a consent form and were
submitted to an interview, physical examination, and
thoracocentesis followed by pleural biopsy with Cope’s
needle. Patients were excluded from the study if the
diagnostic procedures were not completed or if the
pleural effusion etiology remained undetermined at the
end of the diagnostic investigation. Pleural effusion was
deemed limited if it affected less than one third of the
hemithorax, moderate if it affected between one third
and two thirds of the hemithorax, and extensive if it
affected more than two thirds of the hemithorax. This
study was approved by the Research Ethics Committees
of the Federal University of Rio de Janeiro and of the
State Foundation of Health Research and Production of
Porto Alegre, Brazil.
Clinical specimens
Two pleural biopsy fragments and an aliquot of pleural
fluid were stained using the Ziehl-Neelsen method and
cultured in Löwenstein Jensen and Sabouraud medium
following standard protocols [12]. All specimens with
positive mycobacteria culture results were tested using
biochemical methods to distinguish M. tuberculosis
from other nontuberculous mycobacteria. Three
pleural biopsy fragments were submitted to histopatho-
logical examination after hematoxylin and eosin stain-
ing, and an aliquot of pleural fluid was stained using
the Papanicolaou method. Immediately after pleural
fluid collection, an aliquot of 500 μL was frozen at
-20°C and sent to the State Foundation of Health
Research and Production of Porto Alegre for real-time
PCR testing.
Pleural TB definition
A diagnosis of pleural TB was made using the following
tests: AFB smear, the growth of M. tuberculosis (MTB)
in pleural fluid or pleural biopsy tissue, the presence of
granulomatous inflammation in histopathologic study of
the pleural biopsy tissue, or the resolution of clinical
and radiograph abnormalities after six months of stan-
dard antituberculosis treatment (clinical diagnosis).
DNA extraction
DNA was extracted from clinical specimens according
to previously described methodology with modifications
[13]. Briefly, pleural fluid samples were concentrated by
centrifugation, and 100 μL of lysis buffer (8 M guanidine
hydrochloride, 0.08 M Tris HCl, 0.04 M EDTA and 2%
Triton X-100) was added to the pellet and vortexed.
Lysed samples were boiled for 10 min and centrifuged,
and the resultant supernatants were transferred to a
tube containing 2.5 μL of silica suspension. After centri-
fugation, the supernatant was removed, and the pellet
was washed twice with washing buffer (8 M guanidine
hydrochloride and 0.08 M Tris HCl) and once with 70%
ethanol. The tubes were dried with closed lids at 56°C
for 10 min and with open lids at room temperature for
5 min. Elution buffer (1× TE) was added, and the tubes
were homogenized and incubated for 10 min at 56°C.
After centrifugation, the supernatant was collected for
further experimentation. An extraction negative control
(tube containing no organisms) and an extraction posi-
tive control (dilution of a commercial M. tuberculosis
H37Rv reference strain ATCC27294 containing 50 col-
ony forming units) were processed in each set of DNA
extractions.
Real-time PCR assay
Amplification reactions were performed with primers
INS-1/INS-2 as previously described, which generated a
245-base pair (bp) amplification product [14]. PCR was
performed using the ABI Prism 7500 system (Applied
Biosystems, Foster City, California), and the amplified
product was detected with SYBR Green I dye. The reac-
tion was optimized to obtain the best amplification
kinetics. The final reaction volume (20 μL) contained a
mixture of 5 μL of extracted target DNA, 10 μL (0.8 ×)
of SYBR Green PCR Master Mix (Applied Biosystems),
primers INS-1/INS-2 (5 pmol) and water. After 2 min of
incubation at 50°C and 10 min at 95°C, 40 cycles of
amplification were performed with a thermal profile of
95°C for 15 sec and 68 °C for 1 min. A final cycle (95°C
for 15 sec, 60°C for 1 min, 95°C for 15 sec) was added
for the dissociation curve. The amplification and disso-
ciation curves were analyzed with 7500 System Software
(Applied Biosystems) with threshold and baseline analy-
sis autodefined by the software. A negative control
(master mix with water instead of template DNA) and a
positive control (pAMP-1 plasmid containing an IS6110
245-bp inserted fragment) were included for each set of
PCRs. The sample was defined as positive when it had a
detectable cycle threshold (Ct) and the melting tempera-
ture (Tm) was the same as for the positive control
(88.8°C). Our group has obtained successful results
using the IS6110 region to detect M. tuberculosis
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complex DNA, and thus this region was chosen for the
study [15,16].
Presence of inhibitors
For all specimens with negative results, an internal con-
trol (pAMP-1 plasmid containing an exogenous 600-bp
fragment obtained from the pUC13 plasmid digested
with EcoRI enzyme) was added to the PCR (10 fg/μL,
the detection limit concentration) to evaluate the pre-
sence of inhibitors. This sequence was amplified as
described by Cortez-Herrera et al [17] using the same
primers INS-1/INS-2 to generate a 664 bp amplicon.
PCR products were analyzed using electrophoresis on a
1.5% agarose gel stained with ethidium bromide and
visualized with an ultra-violet illuminator to allow the
identification of the amplicon size [14].
Statistical analysis
The Chi-squared test was used to compare frequencies
between groups, and Fisher’s exact test was used when
the absolute number compared was less than 5. Sensitiv-
ity, specificity, positive predictive value (PPV), negative
predictive value (NPV) and 95% confidence interval (CI)
were calculated. Analysis was performed using SPSS
12.0 software (SPSS Ins. Chicago, IL, USA).
Results
A total of 158 patients were enrolled in the study. Eight
subjects were excluded because they did not complete
all diagnostic procedures. Among the remaining 150
patients, 98 (65.3%) had pleural TB, and 52 (34.7%) had
pleural effusion secondary to other disease (33 neoplasia,
8 unspecified inflammatory disease, 7 pneumonia, 3 ede-
migenic syndrome, and 1 systemic lupus erythematosus).
Among the patients with TB diagnosis, all had a nega-
tive HIV test. A cough was described in 69.4% (68/98),
thoracic pain in 75.5% (74/98), fever in 82.6% (81/98)
and dyspnea in 20.4% (20/98) of the TB patients. Demo-
graphic characteristics of the patients are presented in
Table 1.
Among the pleural TB cases, 4 (4%) were diagnosed
based on the resolution of clinical and radiograph
abnormalities after six months of standard anti-TB
treatment, and 94 (96%) had diagnosis confirmed by
laboratory methods. The most frequent finding was the
demonstration of granuloma in pleural biopsy (88.8%;
87/98 patients). AFB smear in pleural fluid and pleura
tissue specimens contributed one case each (1%). Both
also had cultures positive for MTB. The culture was
positive in pleural fluid and pleural tissue specimens in
30.6% (30/98) and 64.3% (63/98) of the patients,
respectively.
The accuracy of the PCR test for pleural TB diagnosis
is shown in Table 2. Sensitivity and negative predictive
value (NPV) were 42.8% (42/98) and 48.5% (49/101),
respectively, while specificity and positive predictive
value (PPV) were 94.2% (49/52) and 93.3% (42/45),
respectively. Pleural fluid obtained from four TB
patients repeatedly demonstrated inhibition in the
amplification reaction; therefore, inhibition results were
only included in the denominator for test accuracy cal-
culations. Three of the four TB patients with inhibited
PCR results in pleural fluid (75%) were male, white and
presented with unilateral pleural effusion without asso-
ciated pulmonary parenchyma alteration on chest radio-
graphy. All of them had positive cultures from pleural
fluid specimens and demonstration of granuloma in
pleural biopsy.
Among the 98 TB patients, pleural fluid analysis pro-
vided positive results in a total of 60 patients (61.2%),
with 18 specimens positive by culture only, 30 speci-
mens positive by PCR only, and 12 specimens positive
in both methods. Therefore, TB was detected in pleural
fluid by culture in 30.6% (30/98) of the patients and by
PCR testing in 42.9% (42/98) of the patients. Pleural
biopsy analysis provided positive results in a total of 90
patients (91.8%), with 3 specimens positive by culture







Mean age (years) 36 60 <0.01
Gender [n (%)] 0.40
Male 67 (68.4) 32 (61.5)
Female 31 (31.6) 20 (38.5)
Race [n (%)] 0.12
White 45 (46.4) 31 (59.6)
Non-white 52 (53.6) 21 (40.4)
Unknown 1 0
Pleural effusion extension*&[n (%)] 0.03
Limited 25 (25.8) 18 (35.3)
Moderate 59 (60.8) 20 (39.2)
Extensive 13 (13.4) 13 (25.5)
Unknown 1 1
Pleural effusion location* [n (%)] 0.63
Unilateral 93 (95.9) 48 (94.1)
Bilateral 4 (4.1) 3 (5.9)
Unknown 1 1
Parenchyma alteration* [n (%)] 0.22
No 65 (67) 29 (56.9)
Yes 32 (33) 22 (43.1)
Unknown 1 1
* Chest radiographic aspects
& Limited: pleural effusion affecting less than one third of the hemithorax
Moderate: pleural effusion affecting between one third and two thirds of the
hemithorax Extensive: pleural effusion affecting more than two thirds of the
hemithorax.
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only, 27 positive by histopathology only (presence of
granuloma), and 60 specimens positive in both methods.
Therefore, TB in pleural tissue was detected by the cul-
ture in 64.3% (63/98) of the patients and by histopatho-
logic examination in 88.8% (87/98) of the patients.
Table 3 shows the results of real-time PCR, culture for
mycobacteria, and histopathology performed in pleural
fluid and pleura tissue specimens of the 98 TB patients,
including those with solely clinical diagnoses.
Discussion
Molecular methods have been shown to be important
tools for confirming pleural TB diagnosis because of
their high specificity (>90%), but they are non-invasive
and low risk, unlike the gold-standard method of pleural
biopsy [8]. Nevertheless, the sensitivity of PCR testing
has been varied, ranging from 37% - 77% across studies,
mainly due to different target nucleic acid sequences
and the amplification methods used [8]. Low sensitivity
values can be explained by the low bacillary load and
the presence of substances that inhibit amplification in
pleural fluid [18]. Some studies comparing conventional
PCR methods with real-time PCR testing have demon-
strated higher sensitivities for the latter (difference of
about 30% with real-time PCR sensitivity up to 68%)
when both tests are performed in the same specimens,
especially in pleural biopsies [19,20]. In addition, real-
time PCR has the advantages of short turn-around time,
lower risk of sample contamination, and ability to quan-
tify bacterial load, raising interest for its use in pleural
effusion tests [9].
Our study evaluated the real-time PCR testing in
pleural fluid, which does not require an invasive proce-
dure for specimen collection, a fact that should be con-
sidered in a setting where pleural biopsy is not widely
available. Our results demonstrated real-time PCR sensi-
tivity of 42.8% when TB cases are defined based on clin-
ical criteria (with or without laboratory confirmation).
Although we have found higher PCR sensitivity than
other studies evaluating similar clinical specimens and
target nucleic acid sequences for amplification (IS6110)
[21-24], our results corroborate the suboptimal sensitiv-
ity as the main limitation of PCR testing for replacing
conventional diagnostic tests for diagnosis of pleural TB.
Pleural fluid specimens in 4 patients with positive cul-
ture for TB and demonstration of granuloma in pleural
biopsy repeatedly demonstrated inhibition of the nucleic
acid amplification reaction. Nonetheless, even without
these substances and the 4 false negative results, test
sensitivity would not be much improved, from 42.8% to
46.9%. Three false positive samples were observed. This
could be potentially due to cross-contamination that
could have occurred during specimen processing,
although the guidelines for diagnostic methods were fol-
lowed. The guidelines include unidirectional work flow
comprising the physical separation of specimen proces-
sing and reagent preparation and the use of positive and
negative controls during DNA extraction and PCR
amplification [16,25].
Real-time PCR of pleural fluid was able to detect TB
in 30 patients with negative AFB smears and culture in
pleural fluid and in 3 of 4 patients with pleural TB
Table 2 Accuracy of real-time PCR testing in pleural fluid for TB diagnosis








Positive (n = 45) 42 3 42.8 93.3
Negative (n = 101) 52 49 (38.4 - 44.8) 94.2 (83.6 - 97.7) 48.5
Inhibited (n = 4) 4 0 (85.8 - 98.0) (44.2 - 50.4)
Total (n = 150) 98 52
PCR test accuracy was calculated using the inhibition results only in the denominator.
PCR: Polymerase chain-reaction; TB: tuberculosis; Sens: sensitivity; Spec: specificity; PPV: positive predictive value; NPV: negative predictive value; CI: confidence
interval
Table 3 Results of real-time PCR testing, culture for MTB (pleural/tissue specimen), and histopathologic study
(presence of granulomatous inflammation in pleural tissue) among 98* patients with pleural TB diagnosis
Culture for MTB in pleural
fluid
Culture for MTB in pleural
tissue
Histopathologic study of pleural
tissue
positive negative positive negative positive negative Total
Real-time PCR
positive 12 30 27 15 36 6 42 (42.9%)
negative/inhibition 18 38 36 20 51 5
Total 30 (30.6%) 63 (64.3%) 87 (88.8%) 98 (100%)
PCR: Polymerase chain-reaction. MTB: Mycobacterium tuberculosis. *Four patients with pleural TB had a diagnosis based only on clinical criteria, and three of them
had positive PCR results.
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diagnosed based on clinical criteria alone. Therefore,
PCR testing was responsible for an improvement in TB
diagnosis from 30.6% to 42.9% when compared to AFB
smear and culture methods performed on pleural fluid
specimens. In addition, the combined results of culture
and PCR in pleural fluid specimens provided an even
better rate of pleural TB detection of 61.2% (60/98).
Although the best sensitivity was achieved by combining
the results of pleura tissue culture and histopathology
(91.8%, 90/98), the prompt confirmation of tuberculous
pleuritis in about 43% of the patients using the PCR test
would allow early treatment initiation. Rapid diagnosis
and initiation of chemotherapy are essential to prevent
secondary fibrothorax and to avoid subsequent pulmon-
ary or extrapulmonary TB development [5].
Therefore, a negative PCR result does not exclude the
diagnosis of pleural TB, as shown in our study, with
approximately 50% of the patents with a negative PCR
result had a pleural TB diagnosis. Thus, the role of real-
time PCR in pleural fluid specimens of patients sus-
pected of having TB would be to rapidly confirm the
disease without waiting for culture and histopathologic
results. Especially in settings with high TB prevalence,
real-time PCR would provide substantial savings for
both the patient and the health care provider in terms
of an earlier definitive diagnosis, optimum patient care,
improved outcomes, and reduced health-care costs [7].
Conclusion
A real-time PCR assay from pleural fluid specimen is a
useful and non-invasive additional test for fast diagnosis
of pleural TB.
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